Patents Assigned to Acesion Pharma
-
Patent number: 11945811Abstract: A compound of the general formula (I), and the pharmaceutical composition including a compound of formula (I) and optionally a pharmaceutically acceptable additive. Also, the treatment of a cardiac disease, disorder or condition in a mammal, which includes the administration to the mammal a therapeutically effective amount of at least one compound of formula (I), or the pharmaceutically acceptable salt thereof.Type: GrantFiled: August 29, 2023Date of Patent: April 2, 2024Assignee: ACESION PHARMA APSInventors: Antonio Mete, Ulrik Sørensen
-
Publication number: 20230406845Abstract: A compound of the general formula (I), and the pharmaceutical composition including a compound of formula (I) and optionally a pharmaceutically acceptable additive. Also, the treatment of a cardiac disease, disorder or condition in a mammal, which includes the administration to the mammal a therapeutically effective amount of at least one compound of formula (I), or the pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 29, 2023Publication date: December 21, 2023Applicant: ACESION PHARMA APSInventors: Antonio METE, Ulrik SØRENSEN
-
Publication number: 20230399301Abstract: A compound of the general formula (I), and the pharmaceutical composition including a compound of formula (I) and optionally a pharmaceutically acceptable additive. Also, the treatment of a cardiac disease, disorder or condition in a mammal, which includes the administration to the mammal a therapeutically effective amount of at least one compound of formula (I), or the pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 28, 2023Publication date: December 14, 2023Applicant: ACESION PHARMA APSInventors: Antonio METE, Ulrik SØRENSEN
-
Patent number: 11274092Abstract: The present invention relates to a compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.Type: GrantFiled: February 23, 2017Date of Patent: March 15, 2022Assignee: ACESION PHARMA ApSInventors: Ulrik Svane Sørensen, Antonio Mete
-
Patent number: 11168074Abstract: A compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.Type: GrantFiled: August 22, 2018Date of Patent: November 9, 2021Assignee: ACESION PHARMA ApSInventors: Ulrik Svane Sørensen, Antonio Mete
-
Patent number: 11098018Abstract: A compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.Type: GrantFiled: August 13, 2018Date of Patent: August 24, 2021Assignee: ACESION PHARMA ApSInventors: Ulrik Svane Sørensen, Antonio Mete
-
Publication number: 20210188804Abstract: The present invention relates to a compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.Type: ApplicationFiled: February 23, 2017Publication date: June 24, 2021Applicant: ACESION PHARMA ApSInventors: Ulrik Svane SØRENSEN, Antonio METE
-
Publication number: 20200255409Abstract: A compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.Type: ApplicationFiled: August 22, 2018Publication date: August 13, 2020Applicant: ACESION PHARMA ApSInventors: Ulrik Svane SØRENSEN, Antonio METE
-
Publication number: 20200216398Abstract: A compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.Type: ApplicationFiled: August 13, 2018Publication date: July 9, 2020Applicant: ACESION PHARMA ApSInventors: Ulrik Svane SØRENSEN, Antonio METE
-
Publication number: 20150164871Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective amount of a sodium channel inhibitor, in a combination with a small-conductance calcium-activated potassium (SK) channel inhibitor, for the treatment of cardiac arrhythmias.Type: ApplicationFiled: June 13, 2013Publication date: June 18, 2015Applicant: Acesion PharmaInventors: Morten Grunnet, Ulrik Svane Sørensen, Bo Hjorth Bentzen, Jonas Goldin Diness
